EASD 2026: Petrelintide pairs 10.7% weight loss with placebo-like GI tolerability

Phase 2positivepetrelintidePositive

AI Analysis

Summary

Petrelintide demonstrated 10.7% weight loss with placebo-like gastrointestinal tolerability in the Phase II ZUPREME-1 trial, with results presented at EASD 2026 in Milan.

Clinical Trial Data

Phase

Phase II

Primary Endpoint

Met

NCT ID

NCT06662539

Outcome Details

10.7% weight loss with placebo-like GI tolerability

Importance:6/10

Sentiment:

0.75

Phase 2 dataobesity/weight lossGI tolerabilityconference presentationEASD 2026

Related Companies

$TRAX

Read the original article

Published by Clinical Trials Arena on October 2, 2026 12:09 PM

Read Original